Transient alendronate administration to pregnant or lactating mothers prevents bone loss in mice without adverse effects on offspring
Transient alendronate administration to pregnant or lactating mothers prevents bone loss in mice without adverse effects on offspring
复制标题
孕妇或哺乳期母亲短暂服用阿仑膦酸钠可防止小鼠骨质流失，且不会对后代产生不良影响
DOI：
10.1016/j.bone.2021.116133
复制
发表时间：
2021
期刊：
影响因子：
4.1
通讯作者：
Miyamoto Takeshi
中科院分区：
文献类型：
--
作者：
Ito Eri;Sato Yuiko;Kobayashi Tami;Soma Tomoya;Matsumoto Tatsuaki;Kimura Atsushi;Miyamoto Kana;Matsumoto Hideo;Matsumoto Morio;Nakamura Masaya;Sato Kazuki;Miyamoto Takeshi
母亲在怀孕或哺乳期间发生骨代谢变化，可能会降低骨量，导致产后脆性骨折。然而，在怀孕或哺乳期间使用药物来抵消这些影响往往被禁止或强烈劝阻。因此，保护母亲免受脆性骨折的方法尚未建立。在这里，我们表明，骨矿物质密度显着降低，在分娩后的雌性小鼠比年龄匹配的雌性小鼠没有分娩。我们还表明，临时管理的双膦酸盐阿仑膦酸钠，无论是之前或刚刚怀孕后，对雌性小鼠的保护骨丢失由于怀孕或哺乳，并没有对后代的不良影响，如生长迟缓。此外，我们表明，阿仑膦酸钠给药的雌性小鼠在哺乳期是有效的增加骨量的母亲没有促进骨异常或生长迟缓的后代。哺乳期给予阿仑膦酸钠的雌性小鼠乳汁中的钙水平与未给予阿仑膦酸钠的母鼠乳汁中的钙水平相当。总之，我们建议母亲服用阿仑膦酸钠可以预防妊娠期和哺乳期的骨质流失和脆性骨折。
Changes in bone metabolism occur in mothers during pregnancy or lactation that may decrease bone mass and result in fragility fractures after partum. However, use of drugs during pregnancy or lactation to counteract these effects is often prohibited or strongly discouraged. Therefore, approaches to protect mothers from fragility fractures have not been established. Here we show that bone mineral density was significantly lower in female mice after partum than in age-matched female mice without partum. We also show that temporary administration of the bisphosphonate alendronate, either just before or just after pregnancy, to female mice was protective against bone loss due to pregnancy or lactation and had no adverse effects on offspring, such as growth retardation. Furthermore, we show that alendronate administration to female mice during lactation was effective in increasing bone mass in mothers without promoting bone abnormalities or growth retardation in offspring. Calcium levels in milk from female mice administered alendronate during lactation were equivalent to those in milk from mothers not treated with alendronate. Overall, we propose that alendronate administration to mothers could prevent bone loss and fragility fractures during pregnancy and lactation.